Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) has provided an update.
On March 12, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion of counsel covering shares of common stock issued and sold under its at-the-market equity offering program established under a September 5, 2025 sales agreement with HC Wainwright & Co., LLC. The updated opinion leaves the program’s terms unchanged but formally confirms the validity of shares that may be sold and clarifies certain legal matters related to the offering, providing added regulatory certainty for the company and its investors.
The most recent analyst rating on (SXTP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Neutral.
The score is held down primarily by very weak fundamentals (outsized losses and ongoing cash burn) and a significant Nasdaq delisting risk. Technical signals are comparatively supportive, but valuation is constrained by continued unprofitability and no dividend support.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. operates in the pharmaceutical sector, focusing on the development and commercialization of medicines, with its equity financing activities supported by an at-the-market equity offering program arranged through HC Wainwright & Co., LLC to issue and sell shares of its common stock.
Average Trading Volume: 4,541,827
Technical Sentiment Signal: Sell
Current Market Cap: $5.09M
Find detailed analytics on SXTP stock on TipRanks’ Stock Analysis page.